Allakos has been granted a patent for methods and compositions using anti-Siglec-7 antibodies with reduced effector function for cancer treatment. The patent includes specific antibody sequences and modifications to enhance stability and reduce effector function. GlobalData’s report on Allakos gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Allakos, Peptide pharmacophores was a key innovation area identified from patents. Allakos's grant share as of April 2024 was 17%. Grant share is based on the ratio of number of grants to total number of patents.
Anti-siglec-7 antibody for cancer treatment
A recently granted patent (Publication Number: US11912766B2) discloses an anti-Siglec-7 antibody designed to bind to Siglec-7, featuring a variant Fc region with specific amino acid modifications aimed at reducing effector function or enhancing antibody stability compared to the native Fc region. The antibody includes various heavy chain variable regions paired with specific light chain variable regions, each with distinct amino acid sequences, as outlined in the patent claims.
Furthermore, the patent details additional modifications within the variant Fc region that target specific positions to reduce effector function or increase antibody stability. The patent also covers the incorporation of these modifications in different combinations to achieve the desired effects. Additionally, the patent extends to include the use of the anti-Siglec-7 antibody in bispecific or multi-specific antibody formats, broadening the scope of potential applications for this novel antibody technology.
To know more about GlobalData’s detailed insights on Allakos, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
